Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;60(1):122-124.
doi: 10.1111/ijd.15313. Epub 2020 Nov 23.

Telogen effluvium: a sequela of COVID-19

Karolina Mieczkowska  1 , Alana Deutsch  1 , Jenna Borok  1 , Anthony K Guzman  1 , Renee Fruchter  1 , Parth Patel  1 , Olivia Wind  1 , Beth N McLellan  1   2 , Ranon E Mann  1 , Caroline P Halverstam  1   2
Affiliations

Telogen effluvium: a sequela of COVID-19

Karolina Mieczkowska et al. Int J Dermatol. 2021 Jan.
No abstract available

PubMed Disclaimer

References

    1. Bandyopadhyay D, Akhtar T, Hajra A, et al. COVID‐19 pandemic: cardiovascular complications and future implications. Am J Cardiovasc Drugs 2020; 20: 311–324. - PMC - PubMed
    1. Marraha F, Al Faker I, Gallouj S. A review of the dermatological manifestations of coronavirus disease 2019 (COVID‐19). Dermatol Res Pract 2020; 2020: 9360476. - PMC - PubMed
    1. Asghar F, Shamim N, Farooque U, et al. Telogen effluvium: a review of the literature. Cureus 2020; 12: e8320. - PMC - PubMed
    1. Fabbrocini G, Cantelli M, Masara A, et al. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol 2018; 4: 203–211. - PMC - PubMed
    1. Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID‐19 emergency: psychological implications. Dermatol Ther 2020: e13648. 10.1111/dth.13648 - DOI - PMC - PubMed

Supplementary concepts